We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma.
- Authors
Hawkes, E. A.; Lewis, K. L.; Doo, N. Wong; Patil, S. S.; Miskin, H. P.; Sportelli, P.; Kolibaba, K. S.; Normant, E.; Turpuseema, T.; Cheah, C. Y.
- Abstract
TG-1801 is a CD19/CD47 bispecific antibody designed to selectively block CD47 on CD19+ cells, while retaining a functional IgG1 Fc domain. First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients with B-Cell Lymphoma B Introduction: b CD19 is an established target of multiple B-cell lymphoma therapies.
- Subjects
BISPECIFIC antibodies; RICHTER syndrome; LYMPHOMAS
- Publication
Hematological Oncology, 2023, Vol 41, p579
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_434